NeoloMed BioSciences has entered into a lab partner agreement to deploy Radient Pharmaceuticals' Onko-Sure in its networks of physicians' offices and hospitals in New Jersey, Connecticut, Delaware, Pennsylvania, Washington,Virginia and Maryland.
Onko-Sure is a FDA cleared non-invasive cancer blood test which aids in monitoring colorectal cancer during treatment and for post-treatment recurrence monitoring.
NeoloMed CEO Faribouz Payvandi said backed by compelling published clinical data and FDA clearance, they believe it will provide a beneficial new diagnostic tool for doctors tracking disease treatment and recurrence for their colorectal cancer patients.
Radient Pharmaceuticals chairman and CEO Douglas MacLellan said their goal is to expand the availability of Onko-Sure throughout the US and to work with regional and national diagnostics labs in doing so.
Onko-Sure has also received regulatory approval outside of the US as a general cancer tumor marker, as well as for lung cancer detection, treatment and recurrence monitoring.